Cognition Therapeutics Inc

NASDAQ:CGTXUnited States

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate CT1812 in clinical programs in Alzheimer's disease, dementia with Lewy bodies and dry age-related macular degeneration (dry AMD). Its lead product candidate, CT1812, is an investigational orally delivered, small molecule modulator that penetrates the blood-brain and blood-retina barriers and binds selectively to the sigma-2 receptor (S2R) complex; and through its modulation of S2R restores normal function of synapses, as well as critical cellular processes such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling, lipid membrane-bound protein trafficking and receptor stabilization at the cell surface. It is developing other product candidates in the area of synucleinopathies.

Contact Information

Headquarters

Suite 261, 2403 Sidney StreetPITTSBURGH, PA, United States 15203

Phone

412-770-1621

Fax

302-697-4597

Executives

Non-Executive Independent Chairman of the Board

Jack Khattar

President, Chief Executive Officer, Director

Lisa Ricciardi

Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer

John Doyle

Chief Medical Officer, Head of R&D

Anthony Caggiano

Independent Director

Aaron Fletcher